Developer docs
API playgroundTry for free, no card

Search company profiles

Synapse Biomedical

Full company profile

uuid0008ku7

Namestring
Synapse Biomedical
Legal namestring
Synapse Biomedical Inc.
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Synapse Biomedical Inc. is a privately held, Oberlin, Ohio-based medical device company founded in 2002 that develops and commercializes neurostimulation products for the diaphragm. Its core commercial offering is the FDA-approved NeuRx Diaphragm Pacing System (DPS), which delivers low-level electrical stimulation through electrodes implanted in the diaphragm to condition the muscle and enable patients with high-level spinal cord injuries (typically C1–C5) and ALS-related respiratory insufficiency to reduce or eliminate dependence on mechanical ventilation. The company has expanded its portfolio with the TransAeris System, a temporary (up to 30-day) diaphragm stimulation device aimed at preventing and treating Ventilator Induced Diaphragm Dysfunction (VIDD) in ventilated patients, and references a Synchrony neuromodulation product line as a broader platform.

The company operates a niche, hospital-anchored go-to-market: NeuRx DPS and TransAeris are not sold directly to patients; they are implanted by board-certified laparoscopic surgeons at qualified treatment centers, with patient referrals routed through a physician locator on the company's website. Synapse generates revenue primarily through hardware sales of the pacing systems to those centers and recurring supplies (electrodes, accessories) fulfilled through U.S. DME suppliers such as Edgepark Medical Supplies and Shepherd Apothecary, with Medicare, Medicaid, and private insurance providing reimbursement for eligible patients. Commercial reach is delivered via a network of regional distribution partners across 24 countries (e.g., Aurora BioScience in Australia, USCI Japan, Perla Health Care for Spain/Italy, UPNORTH MEDICAL for Scandinavia) and a European subsidiary, Synapse Biomedical Europe, headquartered in Enghien les Bains, France.

The company cites clinical outcomes including a 100% success rate in achieving tidal volumes in patients with intact phrenic nerve during trials, 25 of 50 high-level SCI patients achieving full-time diaphragm pacing and ventilator liberation, and a median survival of over 16 months post-implant with NeuRx DPS and non-invasive ventilation for ALS patients. Over 2,000 patients have been treated cumulatively across the network. The leadership team is led by founder Anthony Ignagni (President & CEO), with Timothy Crish as VP of Product Development & Operations, James E. Gelbke as Director of Advanced Manufacturing, and Moustapha Diop as Chief Operating Officer and Managing Director for Europe. Capital sources disclosed include JumpStart Inc. (2006, $270K), an undated 2010 round ($433K), Ohio Third Frontier (2013, $2.4M), and Vivo Capital (2015, undisclosed), with no acquisitions, IPO, or leadership transitions reported in the available data.

Short descriptiontext

Synapse Biomedical is an Oberlin, Ohio-based medical device company that develops and commercializes FDA-approved diaphragm pacing systems—NeuRx DPS for spinal cord injury and ALS patients and TransAeris for ventilator-induced diaphragm dysfunction—sold through qualified treatment centers and international distribution partners in 24 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOberlin, United States
HQ citystring
Oberlin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diaphragm pacing systems, neurostimulation medical devices, respiratory neurostimulation, ventilator weaning technology, spinal cord injury devices
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurostimulation Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Synapse Biomedical generates revenue through the sale of its FDA-approved diaphragm pacing systems (NeuRx DPS and TransAeris). The devices are sold to treatment centers and healthcare facilities where surgical implantation procedures are performed by qualified surgeons. Revenue is derived from device sales, supply ordering (electrodes, accessories), and related medical supplies through authorized DME suppliers.

synapsebiomedical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NeuRx DPS
Description

FDA-approved diaphragm pacing system for spinal cord injury and ALS patients to decrease reliance on mechanical ventilators

synapsebiomedical.com
+2 more records
Core offering1 text field

Synapse Biomedical designs, manufactures, and sells FDA-approved neurostimulation medical devices that electrically stimulate the diaphragm muscle to reduce or eliminate dependence on mechanical ventilation. Its flagship NeuRx DPS® is implanted via a minimally invasive laparoscopic procedure for spinal cord injury and ALS patients, the TransAeris System® provides temporary stimulation to prevent ventilator-induced diaphragm dysfunction, and the Synchrony® platform extends its neurostimulation product line. Devices are sold to qualified hospitals and treatment centers, with ongoing supplies distributed via authorized DME suppliers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% success rate in achieving tidal volumes in patients with intact phrenic nerve
+4 more records
Product overview1 text field

Synapse Biomedical is dedicated to the research, development, and commercialization of life-altering neurostimulation products. The company offers a portfolio of diaphragm pacing systems including the FDA-approved NeuRx DPS® for spinal cord injury and ALS patients, the TransAeris System® for temporary stimulation to prevent ventilator-induced diaphragm dysfunction, and the Synchrony® product line—all designed to reduce reliance on mechanical ventilation through electrical stimulation of the diaphragm.

Product and service1 record
1NeuRx DPS® (Diaphragm Pacing System)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Aurora BioScience Pty Ltd (Australia)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner for Synapse Biomedical products in Australia. Located in Bella Vista, NSW, providing local sales and support for NeuRx DPS customers in Australia.

synapsebiomedical.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner in Brazil serving Porto Alegre region with NeuRx DPS products and support.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner in Colombia based in Bogota, providing NeuRx DPS sales and support services.

4ECUASURGICAL S.A. (Ecuador)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner in Ecuador serving Quito and surrounding regions with NeuRx DPS products.

synapsebiomedical.com
5USCI Japan, Ltd.
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner for Synapse Biomedical products in Japan. Located in Tokyo, serving the Japanese market for NeuRx DPS.

synapsebiomedical.com
6Global Damon Pharma Co. Ltd. (South Korea)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner in South Korea based in Seoul, providing NeuRx DPS products and support.

synapsebiomedical.com
7Medlion Life Science Technology (Taiwan)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner in Taiwan serving Taipei City region with NeuRx DPS products.

synapsebiomedical.com
8Perla Health Care (Spain & Italy)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner covering Spain and Italy markets for Synapse Biomedical products.

synapsebiomedical.com
9UPNORTH MEDICAL (Scandinavia)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Managing Director Thomas Möller leads distribution operations for Scandinavia from Kristianstad, Sweden.

synapsebiomedical.com
10Edgepark Medical Supplies
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

DME supplier for NeuRx DPS supplies serving customers anywhere in the United States. Located in Twinsburg, Ohio.

synapsebiomedical.com
11Shepherd Apothecary
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

DME supplier for NeuRx DPS supplies anywhere in the United States. Located in Atlanta, Georgia.

synapsebiomedical.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient advocacy organization providing resources and support for ALS patients, referenced as a resource partner on Synapse Biomedical website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient advocacy organization referenced as a resource partner for ALS and neuromuscular disease patients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient advocacy organization for spinal cord injury patients, referenced as a resource partner.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Avery manufactures the Mark IV Breathing Pacemaker, a phrenic nerve/diaphragm pacing system for ventilator-dependent patients with SCI and other conditions. It is the most direct competitor to Synapse Biomedical's NeuRx DPS in implantable diaphragm stimulation.

TypeBroad incumbent
Description

Inspire markets an implantable neurostimulation system (hypoglossal nerve stimulation) for obstructive sleep apnea. Comparable to Synapse as an FDA-approved, implanted neurostim device company targeting a respiratory/sleep-related patient population.

TypeBroad incumbent
Description

Medtronic is a global leader in implantable neurostimulation (spinal cord stimulation, deep brain stimulation, sacral nerve stimulation) and broader respiratory care. Comparable as a broad incumbent with deep R&D, sales, and reimbursement infrastructure that Synapse lacks.

TypeBroad incumbent
Description

Boston Scientific operates one of the largest implantable neurostimulation franchises (spinal cord, deep brain, and peripheral nerve stimulation). Relevant peer as a broad incumbent in the implantable neurostimulation space in which Synapse competes.

5Abbott (formerly St. Jude Medical)
TypeBroad incumbent
Description

Abbott's neuromodulation business includes spinal cord stimulation and dorsal root ganglion therapy. Comparable as a broad incumbent competing for the same hospital and payer relationships that Synapse relies on for diaphragm pacing.

TypeEmerging player
Description

Nevro is a focused neuromodulation company with its 10 kHz HF10 spinal cord stimulation system. Comparable as a specialty implantable neurostim company competing for the same hospital channel and reimbursement codes.

TypeBroad incumbent
Description

LivaNova historically developed phrenic nerve/diaphragm stimulation (Atrostim) and remains active in vagus nerve stimulation (VNS) for epilepsy and depression. Comparable neuromodulation incumbent with overlapping respiratory-neurostim heritage.

TypeEmerging player
Description

Axonics is a focused implantable neurostimulation company (sacral and now pudendal nerve stimulation). Comparable as a small-cap, growth-oriented neurostim specialist competing for hospital-based implant adoption.

TypeBroad incumbent
Description

ResMed is a global leader in mechanical ventilation and non-invasive respiratory support — the incumbent standard of care that NeuRx DPS displaces and that competes against TransAeris in the ICU channel.

TypeBroad incumbent
Description

Philips Respironics is a major ICU and home mechanical ventilation franchise. Comparable as the dominant incumbent whose installed base and clinical workflow integrations Synapse must work around when expanding diaphragm pacing into the ICU.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synapse Biomedical

Neurostimulation Medical Devicessynapsebiomedical.com

Synapse Biomedical is an Oberlin, Ohio-based medical device company that develops and commercializes FDA-approved diaphragm pacing systems—NeuRx DPS for spinal cord injury and ALS patients and TransAeris for ventilator-induced diaphragm dysfunction—sold through qualified treatment centers and international distribution partners in 24 countries.

What Synapse Biomedical does

Synapse Biomedical Inc. is a privately held, Oberlin, Ohio-based medical device company founded in 2002 that develops and commercializes neurostimulation products for the diaphragm. Its core commercial offering is the FDA-approved NeuRx Diaphragm Pacing System (DPS), which delivers low-level electrical stimulation through electrodes implanted in the diaphragm to condition the muscle and enable patients with high-level spinal cord injuries (typically C1–C5) and ALS-related respiratory insufficiency to reduce or eliminate dependence on mechanical ventilation. The company has expanded its portfolio with the TransAeris System, a temporary (up to 30-day) diaphragm stimulation device aimed at preventing and treating Ventilator Induced Diaphragm Dysfunction (VIDD) in ventilated patients, and references a Synchrony neuromodulation product line as a broader platform.

The company operates a niche, hospital-anchored go-to-market: NeuRx DPS and TransAeris are not sold directly to patients; they are implanted by board-certified laparoscopic surgeons at qualified treatment centers, with patient referrals routed through a physician locator on the company's website. Synapse generates revenue primarily through hardware sales of the pacing systems to those centers and recurring supplies (electrodes, accessories) fulfilled through U.S. DME suppliers such as Edgepark Medical Supplies and Shepherd Apothecary, with Medicare, Medicaid, and private insurance providing reimbursement for eligible patients. Commercial reach is delivered via a network of regional distribution partners across 24 countries (e.g., Aurora BioScience in Australia, USCI Japan, Perla Health Care for Spain/Italy, UPNORTH MEDICAL for Scandinavia) and a European subsidiary, Synapse Biomedical Europe, headquartered in Enghien les Bains, France.

The company cites clinical outcomes including a 100% success rate in achieving tidal volumes in patients with intact phrenic nerve during trials, 25 of 50 high-level SCI patients achieving full-time diaphragm pacing and ventilator liberation, and a median survival of over 16 months post-implant with NeuRx DPS and non-invasive ventilation for ALS patients. Over 2,000 patients have been treated cumulatively across the network. The leadership team is led by founder Anthony Ignagni (President & CEO), with Timothy Crish as VP of Product Development & Operations, James E. Gelbke as Director of Advanced Manufacturing, and Moustapha Diop as Chief Operating Officer and Managing Director for Europe. Capital sources disclosed include JumpStart Inc. (2006, $270K), an undated 2010 round ($433K), Ohio Third Frontier (2013, $2.4M), and Vivo Capital (2015, undisclosed), with no acquisitions, IPO, or leadership transitions reported in the available data.

Synapse Biomedical firmographics

Firmographics
Name
Synapse Biomedical
Legal name
Synapse Biomedical Inc.
Website
https://synapsebiomedical.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Synapse Biomedical is an Oberlin, Ohio-based medical device company that develops and commercializes FDA-approved diaphragm pacing systems—NeuRx DPS for spinal cord injury and ALS patients and TransAeris for ventilator-induced diaphragm dysfunction—sold through qualified treatment centers and international distribution partners in 24 countries.
Ownership category
akta.pro rank

Synapse Biomedical industry classification

Industry
Product category
Neurostimulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management

Keywords

  • Diaphragm pacing systems
  • Neurostimulation medical devices
  • Respiratory neurostimulation
  • Ventilator weaning technology
  • Spinal cord injury devices

Where Synapse Biomedical is headquartered

Location

Headquarters

HQ city
Oberlin
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Synapse Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Synapse Biomedical generates revenue through the sale of its FDA-approved diaphragm pacing systems (NeuRx DPS and TransAeris). The devices are sold to treatment centers and healthcare facilities where surgical implantation procedures are performed by qualified surgeons. Revenue is derived from device sales, supply ordering (electrodes, accessories), and related medical supplies through authorized DME suppliers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Synapse Biomedical product offering

Product offering

Core offering

Synapse Biomedical designs, manufactures, and sells FDA-approved neurostimulation medical devices that electrically stimulate the diaphragm muscle to reduce or eliminate dependence on mechanical ventilation. Its flagship NeuRx DPS® is implanted via a minimally invasive laparoscopic procedure for spinal cord injury and ALS patients, the TransAeris System® provides temporary stimulation to prevent ventilator-induced diaphragm dysfunction, and the Synchrony® platform extends its neurostimulation product line. Devices are sold to qualified hospitals and treatment centers, with ongoing supplies distributed via authorized DME suppliers.

Product overview

Synapse Biomedical is dedicated to the research, development, and commercialization of life-altering neurostimulation products. The company offers a portfolio of diaphragm pacing systems including the FDA-approved NeuRx DPS® for spinal cord injury and ALS patients, the TransAeris System® for temporary stimulation to prevent ventilator-induced diaphragm dysfunction, and the Synchrony® product line—all designed to reduce reliance on mechanical ventilation through electrical stimulation of the diaphragm.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuRx DPS: FDA-approved diaphragm pacing system for spinal cord injury and ALS patients to decrease reliance on mechanical ventilators
  • TransAeris
  • Synchrony

Products and services

  • NeuRx DPS® (Diaphragm Pacing System)

Quantifiable outcome

  • 100% success rate in achieving tidal volumes in patients with intact phrenic nerve
  • +4 more outcomes

Companies that use Synapse Biomedical

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Synapse Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Synapse Biomedical partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered regional and minor.

  • Aurora BioScience Pty Ltd (Australia)regionalChannel Partner/ Reseller/ DistributorInternational distribution partner for Synapse Biomedical products in Australia. Located in Bella Vista, NSW, providing local sales and support for NeuRx DPS customers in Australia.
  • Jomhedica (Brazil)regionalChannel Partner/ Reseller/ DistributorInternational distribution partner in Brazil serving Porto Alegre region with NeuRx DPS products and support.
  • Biomedisys S.A.S. (Colombia)regionalChannel Partner/ Reseller/ DistributorInternational distribution partner in Colombia based in Bogota, providing NeuRx DPS sales and support services.
  • ECUASURGICAL S.A. (Ecuador)regionalChannel Partner/ Reseller/ DistributorInternational distribution partner in Ecuador serving Quito and surrounding regions with NeuRx DPS products.
  • USCI Japan, Ltd.regionalChannel Partner/ Reseller/ DistributorInternational distribution partner for Synapse Biomedical products in Japan. Located in Tokyo, serving the Japanese market for NeuRx DPS.
  • Global Damon Pharma Co. Ltd. (South Korea)regionalChannel Partner/ Reseller/ DistributorInternational distribution partner in South Korea based in Seoul, providing NeuRx DPS products and support.
  • Medlion Life Science Technology (Taiwan)regionalChannel Partner/ Reseller/ DistributorInternational distribution partner in Taiwan serving Taipei City region with NeuRx DPS products.
  • Perla Health Care (Spain & Italy)regionalChannel Partner/ Reseller/ DistributorInternational distribution partner covering Spain and Italy markets for Synapse Biomedical products.
  • UPNORTH MEDICAL (Scandinavia)regionalChannel Partner/ Reseller/ DistributorManaging Director Thomas Möller leads distribution operations for Scandinavia from Kristianstad, Sweden.
  • Edgepark Medical SuppliesregionalChannel Partner/ Reseller/ DistributorDME supplier for NeuRx DPS supplies serving customers anywhere in the United States. Located in Twinsburg, Ohio.
  • Shepherd ApothecaryregionalChannel Partner/ Reseller/ DistributorDME supplier for NeuRx DPS supplies anywhere in the United States. Located in Atlanta, Georgia.
  • ALS AssociationminorStrategic or Co-development PartnerPatient advocacy organization providing resources and support for ALS patients, referenced as a resource partner on Synapse Biomedical website.
  • Muscular Dystrophy Association (MDA)minorStrategic or Co-development PartnerPatient advocacy organization referenced as a resource partner for ALS and neuromuscular disease patients.
  • United Spinal AssociationminorStrategic or Co-development PartnerPatient advocacy organization for spinal cord injury patients, referenced as a resource partner.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Synapse Biomedical competitors and assessment

Company assessment

Direct peers

  • Avery Biomedical Devices: Avery manufactures the Mark IV Breathing Pacemaker, a phrenic nerve/diaphragm pacing system for ventilator-dependent patients with SCI and other conditions. It is the most direct competitor to Synapse Biomedical's NeuRx DPS in implantable diaphragm stimulation.

Broad incumbents

  • Inspire Medical Systems: Inspire markets an implantable neurostimulation system (hypoglossal nerve stimulation) for obstructive sleep apnea. Comparable to Synapse as an FDA-approved, implanted neurostim device company targeting a respiratory/sleep-related patient population.
  • Medtronic: Medtronic is a global leader in implantable neurostimulation (spinal cord stimulation, deep brain stimulation, sacral nerve stimulation) and broader respiratory care. Comparable as a broad incumbent with deep R&D, sales, and reimbursement infrastructure that Synapse lacks.
  • Boston Scientific: Boston Scientific operates one of the largest implantable neurostimulation franchises (spinal cord, deep brain, and peripheral nerve stimulation). Relevant peer as a broad incumbent in the implantable neurostimulation space in which Synapse competes.
  • Abbott (formerly St. Jude Medical): Abbott's neuromodulation business includes spinal cord stimulation and dorsal root ganglion therapy. Comparable as a broad incumbent competing for the same hospital and payer relationships that Synapse relies on for diaphragm pacing.
  • LivaNova: LivaNova historically developed phrenic nerve/diaphragm stimulation (Atrostim) and remains active in vagus nerve stimulation (VNS) for epilepsy and depression. Comparable neuromodulation incumbent with overlapping respiratory-neurostim heritage.
  • ResMed: ResMed is a global leader in mechanical ventilation and non-invasive respiratory support — the incumbent standard of care that NeuRx DPS displaces and that competes against TransAeris in the ICU channel.
  • Philips (Respironics): Philips Respironics is a major ICU and home mechanical ventilation franchise. Comparable as the dominant incumbent whose installed base and clinical workflow integrations Synapse must work around when expanding diaphragm pacing into the ICU.

Emerging players

  • Nevro: Nevro is a focused neuromodulation company with its 10 kHz HF10 spinal cord stimulation system. Comparable as a specialty implantable neurostim company competing for the same hospital channel and reimbursement codes.
  • Axonics: Axonics is a focused implantable neurostimulation company (sacral and now pudendal nerve stimulation). Comparable as a small-cap, growth-oriented neurostim specialist competing for hospital-based implant adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Synapse Biomedical social profiles

Digital presence

Synapse Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synapse Biomedical leadership team

Management profile

Number of profiles

Profiles4 records

Synapse Biomedical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Synapse Biomedical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synapse Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synapse Biomedical

What does Synapse Biomedical do?

Synapse Biomedical designs, manufactures, and sells FDA-approved neurostimulation medical devices that electrically stimulate the diaphragm muscle to reduce or eliminate dependence on mechanical ventilation. Its flagship NeuRx DPS® is implanted via a minimally invasive laparoscopic procedure for spinal cord injury and ALS patients, the TransAeris System® provides temporary stimulation to prevent ventilator-induced diaphragm dysfunction, and the Synchrony® platform extends its neurostimulation product line. Devices are sold to qualified hospitals and treatment centers, with ongoing supplies distributed via authorized DME suppliers.

Is Synapse Biomedical a public or private company?

Synapse Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Synapse Biomedical founded?

Synapse Biomedical was founded in 2002. It employs 11 to 50 people.

Where is Synapse Biomedical based?

Synapse Biomedical is headquartered in Oberlin, United States, in the North America region.

How does Synapse Biomedical make money?

One revenue line is on record: medical Device Sales.

Who are Synapse Biomedical's main competitors?

Avery Biomedical Devices is listed as a direct peer. Broad incumbents are Inspire Medical Systems, Medtronic, Boston Scientific, Abbott (formerly St. Jude Medical), LivaNova, ResMed and Philips (Respironics). Emerging players are Nevro and Axonics.

Does Synapse Biomedical have an API?

No public API is recorded for Synapse Biomedical.

What industry is Synapse Biomedical in?

Synapse Biomedical's product category is Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKANAM, Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comGlobal Neuromodulation Market to grow at a CAGR of 8.95% by 2030, Evaluates DelveInsight | Medtronic, Abbott, Boston Scientific Corp, LivaNova, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical IncDelveInsight projects the global neuromodulation devices market to grow from USD 5.71 billion in 2023 to USD 9.56 billion by 2030, a CAGR of 8.95%. Growth is driven by rising neurological disorders, chronic pain, and an aging population, with North America leading.FierceBiotechSynapse snaps up full FDA approval for diaphragm stimulation systemSynapse Biomedical received full FDA premarket approval for its NeuRx diaphragm pacing system, expanding access for patients with spinal cord injuries beyond the previous humanitarian device exemption limits. The system uses implanted electrodes to stimulate the diaphragm, offering a breathing alternative to ventilators that studies suggest can reduce hospital stays by an average of 19 days and save approximately $140,000 per patient.PR NewswireSynapse Biomedical Wins New Approval for Diaphragm Pacing System to Free Patients from VentilatorsThe FDA granted premarket approval to Synapse Biomedical's NeuRx Diaphragm Pacing System for spinal cord injury patients who rely on mechanical ventilation. The device provides negative pressure ventilation, and hospitals can now implement it without the previous humanitarian device exemption process. The approval aims to improve access and affordability for patients.openPR.comDiaphragm Pacing Therapy System Market Growth Report during 2021-2027 | Lungpacer Medical, Avery Biomedical Devices, Synapse BiomedicalResearch Informatic released a market intelligence report forecasting the global Diaphragm Pacing Therapy System market to reach $9.41 million by 2026, driven by rising incidences of spinal cord injuries and ALS. The report identifies key industry players including Lungpacer Medical, Avery Biomedical Devices, Synapse Biomedical, and Atrotech as major participants in this growing sector.PR NewswireNeuromodulation Market Size Worth $16,333.98 Mn by 2027 by 10.3% CAGR with Impact of Coronavirus Outbreak and Global Analysis & Forecast by The Insight PartnersThe Insight Partners published a market research report projecting the global neuromodulation market to reach $16,333.98 million by 2027, growing at a CAGR of 10.3% from 2019's valuation of $7,613.45 million, driven by rising neurological disorder incidence and technological advancements, though high device costs remain a barrier. The report identifies key market players including Medtronic, Boston Scientific, Abbott, Synapse Biomedical, and Wise Srl, which collectively announced product launches, FDA approvals, funding rounds, and European market expansions between April and October 2020. COVID-19 is expected to create short-term supply chain disruptions but may increase long-term demand as the geriatric population faces greater chronic pain exposure and immunosuppression risks.BioWorldSynapse’s diaphragm pacing system nabs FDA breakthrough statusSynapse Biomedical received FDA breakthrough device designation for its Transaeris diaphragm pacing system, used to wean patients off mechanical ventilation. The minimally invasive device was previously used during the COVID-19 pandemic under emergency use authorization to prevent ventilator-induced diaphragm dysfunction.PR NewswireFDA Grants Breakthrough Designation to Synapse Biomedical's TransAeris® SystemSynapse Biomedical received FDA Breakthrough Therapy Device designation for TransAeris, a temporary diaphragm stimulator designed to help ICU patients wean from mechanical ventilation. The designation expedites regulatory review for devices treating life-threatening or debilitating conditions. The TransAeris system builds on Synapse's existing NeuRx technology, which received FDA and CE Mark approval in 2008 for spinal cord injury patients.PR NewswireDiaphragm Pacing can Enhance Recovery and Weaning from Mechanical Ventilation (MV) in Cardiac SurgerySurgeons at University Hospitals Cleveland Medical Center used Synapse Biomedical's TransAeris DP system to improve outcomes in cardiac surgery patients at risk of prolonged mechanical ventilation, achieving an average extubation time of 6.7 hours with no re-intubations or respiratory complications. The system, authorized under FDA Emergency Use Authorization in April 2020, uses temporary electrodes to stimulate the diaphragm and prevent ventilator-induced diaphragm dysfunction. The findings have broader implications during the COVID-19 pandemic, as the technology could reduce ventilator burden and free up units for other patients in need.PR NewswireSynapse Biomedical obtient une autorisation d'utilisation en urgence de la FDA pour un nouveau système qui aide à sevrer les patients des respirateurs durant la pandémie du COVID-19Synapse Biomedical received FDA Emergency Use Authorization for its TransAeris® Diaphragm Stimulation System to help wean COVID-19 patients from ventilators during the pandemic. The system, which could reduce mechanical ventilation duration by approximately 26%, addresses ventilator-induced diaphragm dysfunction in patients requiring prolonged ventilation, potentially freeing up critical ventilators, ICU beds, and clinical resources. The technology, which already received CE Mark approval and is under clinical investigation in the U.S., builds on the company's existing NeuRx DPS system approved since 2008.